The antiphospholipid syndrome (APS) is characterized by arterial and/or venous thromboses, pregnancy loss, and the presence of anticardiolipin antibodies. The pathogenic mechanisms that lead to these clinical manifestations are incompletely understood. Although a direct pathogenic role of antiphospholipid antibodies has been established, including their role in endothelial cell and platelet activation, there is growing evidence that activation of the complement pathway may contribute to the pathogenesis of APS. Vital information has been obtained from studies exploring the features of pregnancy morbidity and thrombosis using complement deficient murine models. These studies are providing the foundation for the development of new therapeutic options to optimize the management of APS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12016-008-8109-7 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!